All News

The race for a coronavirus disease 2019 (COVID-19) vaccine is one of the most urgent public health challenges, with multiple vaccine candidates entering phase 3 trials and case counts around the world steadily climbing. MJH Life Sciences™ will host a free webinar with the top minds in infectious disease, virology, and vaccinology to discuss the latest trial information on vaccines.

Compared with digital mammography, digital breast tomosynthesis, also called 3-dimensional (3-D) mammography, has been proven superior at effectively detecting breast cancer and leading to fewer recall visits, but more information is needed for how subgroups of women with different breast densities benefit from the screening method, especially those classified as having extremely dense breast tissue.

A meeting at the White House with top pharmaceutical executives has been cancelled after the Trump administration’s executive orders signed this past Friday on the topic drew criticism from the drug industry; Kodak has won a $765 million US government loan to assist in expediting domestic production of drugs to treat several medical conditions and reduce US reliance on foreign supplies; more than a third of patients with mild illness from coronavirus disease 2019 (COVID-19) reported related symptoms that lasted for 2 to 3 weeks after testing positive.

In beginning the first phase 3 clinical trial to examine a vaccine candidate for the coronavirus disease 2019 (COVID-19), Moderna Inc announced that the Trump administration increased funding to expand the trial to 30,000 US participants; employers have considered and some have made it a requirement for employees to sign a waiver to not sue the organization if they are infected by COVID-19 or suffered any injury while working; study finds 1 flu shot can reduce the risk for Alzheimer disease by 17% and 1 pneumonia vaccine before age 75 can reduce the risk by 25%.

IQVIA, a health information technology and clinical research company, recently announced a new collaboration with JDRF, the world’s largest nonprofit funder of type 1 diabetes (T1D) research. Together, the companies plan to develop a real-world research platform to facilitate evidence generation for T1D via non-identified patient-level data and analytics.

The researchers noted that these results can help inform therapeutic decision making and identify opportunities to address barriers to disease-modifying drug (DMD) adherence, which not only improves clinical outcomes but also reaps benefits when it comes to health care costs.

This week, the top managed care news included states suing the Trump administration over an HHS rule on nondiscrimination; experimental vaccines show promise against COVID-19 in healthy subjects; diagnostic delays from COVID-19 may increase cancer-related deaths.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text